A citation-based method for searching scientific literature

Angela Arsova, Thor C Møller, Line Vedel, Jakob Lerche Hansen, Simon R Foster, Karen J Gregory, Hans Bräuner-Osborne. Mol Pharmacol 2020
Times Cited: 5







List of co-cited articles
67 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington's disease.
Khaled S Abd-Elrahman, Alison Hamilton, Shaunessy R Hutchinson, Fang Liu, Ryan C Russell, Stephen S G Ferguson. Sci Signal 2017
34
60

Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
Kathy Sengmany, Junaid Singh, Gregory D Stewart, P Jeffrey Conn, Arthur Christopoulos, Karen J Gregory. Neuropharmacology 2017
32
60

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
Eriene A Youssef, Elizabeth Berry-Kravis, Christian Czech, Randi J Hagerman, David Hessl, Chin Y Wong, Michael Rabbia, Dennis Deptula, Amy John, Russell Kinch,[...]. Neuropsychopharmacology 2018
68
60

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Jorge A Quiroz, Paul Tamburri, Dennis Deptula, Ludger Banken, Ulrich Beyer, Michael Rabbia, Nikhat Parkar, Paulo Fontoura, Luca Santarelli. JAMA Psychiatry 2016
77
60

Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
Kathy Sengmany, Shane D Hellyer, Sabine Albold, Taide Wang, P Jeffrey Conn, Lauren T May, Arthur Christopoulos, Katie Leach, Karen J Gregory. Neuropharmacology 2019
12
60

Metabotropic glutamate receptors and neurodegenerative diseases.
Fabiola M Ribeiro, Luciene B Vieira, Rita G W Pires, Roenick P Olmo, Stephen S G Ferguson. Pharmacol Res 2017
106
60

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
François Tison, Charlotte Keywood, Mark Wakefield, Franck Durif, Jean-Christophe Corvol, Karla Eggert, Mark Lew, Stuart Isaacson, Erwan Bezard, Sonia-Maria Poli,[...]. Mov Disord 2016
82
60

Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
Meredith J Noetzel, Jerri M Rook, Paige N Vinson, Hyekyung P Cho, Emily Days, Y Zhou, Alice L Rodriguez, Hilde Lavreysen, Shaun R Stauffer, Colleen M Niswender,[...]. Mol Pharmacol 2012
99
40


A signaling mechanism from G alpha q-protein-coupled metabotropic glutamate receptors to gene expression: role of the c-Jun N-terminal kinase pathway.
Lu Yang, Limin Mao, Hai Chen, Michael Catavsan, Jonathan Kozinn, Anish Arora, Xianyu Liu, John Q Wang. J Neurosci 2006
46
40


Location and Cell-Type-Specific Bias of Metabotropic Glutamate Receptor, mGlu5, Negative Allosteric Modulators.
Yuh-Jiin Ivy Jong, Steven K Harmon, Karen L O'Malley. ACS Chem Neurosci 2019
7
40

A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors.
Etienne Doumazane, Pauline Scholler, Jurriaan M Zwier, Eric Trinquet, Philippe Rondard, Jean-Philippe Pin. FASEB J 2011
198
40



Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
Jerri M Rook, Meredith J Noetzel, Wendy A Pouliot, Thomas M Bridges, Paige N Vinson, Hyekyung P Cho, Ya Zhou, Rocco D Gogliotti, Jason T Manka, Karen J Gregory,[...]. Biol Psychiatry 2013
77
40

Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.
Ji Won Um, Adam C Kaufman, Mikhail Kostylev, Jacqueline K Heiss, Massimiliano Stagi, Hideyuki Takahashi, Meghan E Kerrisk, Alexander Vortmeyer, Thomas Wisniewski, Anthony J Koleske,[...]. Neuron 2013
379
40

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Fabrizio Stocchi, Olivier Rascol, Alain Destee, Nobutaka Hattori, Robert A Hauser, Anthony E Lang, Werner Poewe, Mark Stacy, Eduardo Tolosa, Haitao Gao,[...]. Mov Disord 2013
100
40

A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease.
Paula Maria Quaglio Bellozi, Giovanni Freitas Gomes, Maria Carolina Machado da Silva, Isabel Vieira de Assis Lima, Carla Ribeiro Álvares Batista, Wellerson de Oliveira Carneiro Junior, Juliana Guimarães Dória, Érica Leandro Marciano Vieira, Rafael Pinto Vieira, Rossimiriam Pereira de Freitas,[...]. Neuropharmacology 2019
9
40

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
40

Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain.
Andrew S Doré, Krzysztof Okrasa, Jayesh C Patel, Maria Serrano-Vega, Kirstie Bennett, Robert M Cooke, James C Errey, Ali Jazayeri, Samir Khan, Ben Tehan,[...]. Nature 2014
289
40

Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes.
I Brabet, M L Parmentier, C De Colle, J Bockaert, F Acher, J P Pin. Neuropharmacology 1998
114
40


Ca(2+)/calmodulin-dependent protein kinase II interacts with group I metabotropic glutamate and facilitates receptor endocytosis and ERK1/2 signaling: role of β-amyloid.
Fitore Raka, Andrea R Di Sebastiano, Stephanie C Kulhawy, Fabiola M Ribeiro, Christina M Godin, Fabiana A Caetano, Stephane Angers, Stephen S G Ferguson. Mol Brain 2015
27
40

Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses.
Yelin Chen, Yi Nong, Cyril Goudet, Kamondanai Hemstapat, Tomas de Paulis, Jean-Philippe Pin, P Jeffrey Conn. Mol Pharmacol 2007
77
40

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
245
40

Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes.
Laura T Haas, Santiago V Salazar, Levi M Smith, Helen R Zhao, Timothy O Cox, Charlotte S Herber, Andrew P Degnan, Anand Balakrishnan, John E Macor, Charles F Albright,[...]. Cell Rep 2017
57
40

Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration.
Sophie Parmentier-Batteur, Julie A O'Brien, Scott Doran, Shannon J Nguyen, Rosemarie Beth Flick, Jason M Uslaner, Hank Chen, Eleftheria N Finger, Theresa M Williams, Marlene A Jacobson,[...]. Neuropharmacology 2012
50
40


Pyk2 uncouples metabotropic glutamate receptor G protein signaling but facilitates ERK1/2 activation.
Alexander A Nicodemo, Macarena Pampillo, Lucimar T Ferreira, Lianne B Dale, Tamara Cregan, Fabiola M Ribeiro, Stephen S G Ferguson. Mol Brain 2010
36
40

Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells.
Nuria Cabello, Jorge Gandía, Daniela C G Bertarelli, Masahiko Watanabe, Carme Lluís, Rafael Franco, Sergi Ferré, Rafael Luján, Francisco Ciruela. J Neurochem 2009
199
40

Organization and functions of mGlu and GABAB receptor complexes.
Jean-Philippe Pin, Bernhard Bettler. Nature 2016
126
40

LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
A E Kingston, P L Ornstein, R A Wright, B G Johnson, N G Mayne, J P Burnett, R Belagaje, S Wu, D D Schoepp. Neuropharmacology 1998
311
40

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Erwan Bezard, Elsa Y Pioli, Qin Li, Françoise Girard, Vincent Mutel, Charlotte Keywood, Francois Tison, Olivier Rascol, Sonia M Poli. Mov Disord 2014
48
40

NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin.
Sudar Alagarsamy, Julie Saugstad, Lee Warren, Isabelle M Mansuy, Robert W Gereau, P Jeffrey Conn. Neuropharmacology 2005
72
40

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Lothar Lindemann, Georg Jaeschke, Aubin Michalon, Eric Vieira, Michael Honer, Will Spooren, Richard Porter, Thomas Hartung, Sabine Kolczewski, Bernd Büttelmann,[...]. J Pharmacol Exp Ther 2011
77
40

N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
K J Gregory, E J Herman, A J Ramsey, A S Hammond, N E Byun, S R Stauffer, J T Manka, S Jadhav, T M Bridges, C D Weaver,[...]. J Pharmacol Exp Ther 2013
33
40

Transduction of group I mGluR-mediated synaptic plasticity by β-arrestin2 signalling.
Andrew G Eng, Daniel A Kelver, Tristan P Hedrick, Geoffrey T Swanson. Nat Commun 2016
27
40

Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Sophie Parmentier-Batteur, Peter H Hutson, Karsten Menzel, Jason M Uslaner, Britta A Mattson, Julie A O'Brien, Brian C Magliaro, Thomas Forest, Craig A Stump, Robert M Tynebor,[...]. Neuropharmacology 2014
66
40

Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model.
Alison Hamilton, Maryam Vasefi, Cheryl Vander Tuin, Robyn J McQuaid, Hymie Anisman, Stephen S G Ferguson. Cell Rep 2016
54
40


Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins.
J C Tu, B Xiao, S Naisbitt, J P Yuan, R S Petralia, P Brakeman, A Doan, V K Aakalu, A A Lanahan, M Sheng,[...]. Neuron 1999
810
40

"Selective" Class C G Protein-Coupled Receptor Modulators Are Neutral or Biased mGlu5 Allosteric Ligands.
Shane D Hellyer, Sabine Albold, Taide Wang, Amy N Y Chen, Lauren T May, Katie Leach, Karen J Gregory. Mol Pharmacol 2018
14
40


Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.
Karen J Gregory, Meredith J Noetzel, Jerri M Rook, Paige N Vinson, Shaun R Stauffer, Alice L Rodriguez, Kyle A Emmitte, Ya Zhou, Aspen C Chun, Andrew S Felts,[...]. Mol Pharmacol 2012
67
40



A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
Ralf Reilmann, Marie-Laure Rouzade-Dominguez, Carsten Saft, Sigurd D Süssmuth, Josef Priller, Anne Rosser, Hugh Rickards, Ludger Schöls, Nicole Pezous, Fabrizio Gasparini,[...]. Mov Disord 2015
54
40

In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery.
Karen J Gregory, Thomas M Bridges, Rocco G Gogliotti, Shaun R Stauffer, Meredith J Noetzel, Carrie K Jones, Craig W Lindsley, P Jeffrey Conn, Colleen M Niswender. ACS Pharmacol Transl Sci 2019
5
40

Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections.
V Mutel, G J Ellis, G Adam, S Chaboz, A Nilly, J Messer, Z Bleuel, V Metzler, P Malherbe, E J Schlaeger,[...]. J Neurochem 2000
54
40


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.